Results 121 to 130 of about 226,492 (355)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Journal of Infectious Diseases, 2018
Background The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials.
A. Cunningham, T. Heineman, Himal Lal, O. Godeaux, R. Chlibek, Shinn-Jang Hwang, J. Mcelhaney, T. Vesikari, C. Andrews, W. Choi, Meral Esen, H. Ikematsu, Martina Kovac Choma, K. Pauksens, S. Ravault, B. Salaun, T. Schwarz, J. Smetana, C. V. Abeele, P. Van den Steen, Ilse Vastiau, L. Weckx, M. Levin   +22 more
semanticscholar   +1 more source

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis

Rheumatology &Autoimmunity, EarlyView.
A systematic review and meta‐analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta‐analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous ...
Yomna W. Mahmoud, Mohamed Ramadan S., Doaa Radwan G., Mariam S. Abdulhafiz, Yassin M. El‐Shnawy, Alaa Alaa H., Sara Naser Sebie, Maryam A. Elashmawi, Husni Zahi M., Mohammad T. Abuawwad, Mohammad J. Taha, Abdulqadir J. Nashwan   +11 more
wiley   +1 more source

Herpes zoster vaccination in systemic lupus erythematosus: the current status

Human Vaccines & Immunotherapeutics, 2019
Among the inflammatory rheumatic diseases, SLE is associated with the highest risk of herpes zoster reactivation relative to age. The reported incidence of herpes zoster infection in SLE ranges from 6.4 to 91.4/1000 patient-years, with main risk factors ...
Chi Chiu Mok
doaj   +1 more source

Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis

British medical journal, 2018
Objective To compare the efficacy, effectiveness, and safety of the herpes zoster live attenuated vaccine with the herpes zoster adjuvant recombinant subunit vaccine or placebo for adults aged 50 and older.
A. Tricco, W. Zarin, R. Cardoso, A. Veroniki, P. Khan, V. Nincic, M. Ghassemi, Rachel Warren, J. P. Sharpe, A. Page, S. Straus   +10 more
semanticscholar   +1 more source

Shingrix: Educating Patients on the New Shingles Vaccine [PDF]

, 2018
Herpes zoster (shingles) is a viral infection that results in a painful rash and has a myriad of long-term complications, including post-herpetic neuralgia- chronic pain that does not resolved despite resolution of the rash.
Jost, Sarah Natasha
core   +1 more source

Herpes zoster ophthalmicus with dependent contralateral edema

Journal of Hospital Medicine, EarlyView.
Tyler B. Larsen
wiley   +1 more source

Sphingosine‐1‐Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety

United European Gastroenterology Journal, EarlyView.
ABSTRACT Ulcerative colitis is a chronic immune‐mediated inflammatory disease of the colon that causes considerable morbidity and increases the risk of colorectal cancer. Several targeted therapies have been developed for moderate‐to‐severe ulcerative colitis, significantly improving its management.
Massimo C. Fantini, Diego Centonze, Giovanni Giacobazzi, Silvia Benemei, Emanuele Romeo   +4 more
wiley   +1 more source

Pregabalin for postherpetic itch: a case report

JA Clinical Reports, 2020
Background Postherpetic itch has not commonly received attention as a complication of herpes zoster because pain predominates over itch in most patients with herpes zoster.
Nobuhiro Shimada, Yasunori Niwa, Kunihisa Hotta, Takashi Igarashi, Mamoru Takeuchi   +4 more
doaj   +1 more source

Has VZV epidemiology changed in Italy? Results of a seroprevalence study [PDF]

, 2017
The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era.
Amodio E., Angelillo I., Bagordo F., Baldo V., Baldovin T., Bandettini R., Bassetti D., Bassi C., Bella A., Bernardini S., Binda S., Bonanni P., Bordonaro P., Brignole G., Cacello E., Caligiuri P., Casalino P., Castiglia P., Cia M., Cicerchia E., Clerico L., Cracchiolo M., D'Agaro P., De Donno A., Del Manso M., Devoti G., Di Giuseppe G., Ditommaso S., Fazii P., Gabutti G., Gallo T., Gamper A., Giandomenico A. M., Giraldi C., Grasso G., Greco F., Guerra G., Guido M., Idolo A., Kuhdari P., Lupi S., Maglione F., Manchia P., Megha M., Pagani E., Passamonti B., Pellegrinelli L., Pelliccioni A. R., Perrone M., Peruzzi M., Piana A., Primache V., Renzoni C., Resciniti C., Romano P., Rossi P., Rota M. C., Sammarco M. L., Schettini S., Schippa S., Sciuto V., Segat L., Stefanati A., Sticchi L., Tiscione E., Trucchi C., Tumolo M. R., Vallerini M., Vargiu P., Vitale F., Zizza A., Zotti C.   +71 more
core   +1 more source

Herpes zoster subunit vaccine for the prevention of herpes zoster

American Journal of Health-System Pharmacy, 2018
Published literature on the efficacy and safety of the herpes zoster (HZ) subunit vaccine (HZ/su vaccine) in reducing the risks of HZ and postherpetic neuralgia (PHN) in adults 50 years of age and older, as well as the vaccine's properties and efficacy relative to live attenuated vaccine, is reviewed.HZ/su vaccine (Shingrix, GlaxoSmithKline) is a ...
Melanie Symoniak, Judianne Slish, Judianne Slish, Pejman Farrokh, Mona A. Gandhi   +4 more
openaire   +4 more sources